AffiliationCentro de Investigacion Medica Aplicada (CIMA) and Clinica Universitaria (CUN), Universidad de Navarra, Spain
MetadataShow full item record
AbstractThe therapeutic potential of host-specific and tumour-specific immune responses is well recognized and, after many years, active immunotherapies directed at inducing or augmenting these responses are entering clinical practice. Antitumour immunization is a complex, multi-component task, and the optimal combinations of antigens, adjuvants, delivery vehicles and routes of administration are not yet identified. Active immunotherapy must also address the immunosuppressive and tolerogenic mechanisms deployed by tumours. This Review provides an overview of new results from clinical studies of therapeutic cancer vaccines directed against tumour-associated antigens and discusses their implications for the use of active immunotherapy.
CitationTherapeutic vaccines for cancer: an overview of clinical trials. 2014: Nat Rev Clin Oncol
JournalNature Reviews Clinical Oncology
- Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
- Authors: Minev BR, Guo F, Gueorguieva I, Kaiser HE
- Issue date: 2002 Nov-Dec
- Cellular vaccine therapies for cancer.
- Authors: Mastrangelo MJ, Sato T, Lattime EC, Maguire HC Jr, Berd D
- Issue date: 1998
- Prediction of response to anticancer immunotherapy using gene signatures.
- Authors: Wang E, Bedognetti D, Marincola FM
- Issue date: 2013 Jul 1
- Active specific immunotherapy: using tumor heterogeneity to successfully fight cancer.
- Authors: Hanna MG Jr, Howard J, Vermorken J
- Issue date: 2014
- Cancer vaccines.
- Authors: Butterfield LH
- Issue date: 2015 Apr 22